Lars Jørgen Østergaard

Why START? Reflections that led to the conduct of this large long-term strategic HIV trial

Research output: Contribution to journal/Conference contribution in journal/Contribution to newspaperEditorialResearchpeer-review

DOI

  • Jens Lundgren
  • ,
  • INSIGHT Strategic Timing of AntiRetroviral Treatment (START) Study Group
  • ,
  • Lars Jørgen Østergaard (Member of author collaboration)
Original languageEnglish
JournalHIV Medicine
Volume16 Suppl 1
Pages (from-to)1-9
Number of pages9
ISSN1464-2662
DOIs
Publication statusPublished - Apr 2015

    Research areas

  • Adult, Anti-Retroviral Agents, Antiretroviral Therapy, Highly Active, CD4 Lymphocyte Count, Cohort Studies, Female, HIV Infections, Humans, Male, Randomized Controlled Trials as Topic, Time Factors, Treatment Outcome

See relations at Aarhus University Citationformats

ID: 99625133